Close

Delta Cargo approves the new Envirotainer Releye RLP container for fleet usage

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Delta Cargo announced that it has approved the Envirotainer Releye RLP for usage on their fleet of aircraft. Envirotainer is the global market leader in secure cold chain solutions for air transportation of pharmaceuticals. With this approval, Delta Cargo can now transport the Releye RLP on their wide-reaching global network, increasing the capacity to meet the ever-growing need for temperature-controlled, high-quality, connected ULD solutions.

“The introduction of the Releye RLP, in combination with our CEIV certified pharma network, provides our customers with more choice when looking for reliable container options to support the growing demand for pharma and vaccine shipments,” said Jannie Davel, Managing Director Cargo Commercial at Delta Cargo.

The Releye provides outstanding environmental performance, delivering up to 90% reduction in CO2 emissions compared to available passive solutions, based on life-cycle analysis. The Releye RLP uses rechargeable batteries to power its electric heating and compressor cooling system and can power its system for over 170 hours on a single charge.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back